Extracorporeal membrane oxygenation is emerging as a vital resource for survival of patients with acute respiratory distress syndrome related to COVID-19. Although recent research provides much insight into the advantages of extracorporeal membrane oxygenation in this patient population, little has been published on its use in pregnancy. This case study describes the use of venovenous extracorporeal membrane oxygenation in a young pregnant woman with acute respiratory distress syndrome due to COVID-19. It illustrates the benefits of a multidisciplinary approach to this treatment modality, allowing time for a fetus to become viable while preserving the life of the mother. In this case, the mother was able to return home after receiving this therapy and resume normal activities of daily living independently.
Skip Nav Destination
Article navigation
Fall 2022
Symposium: Interventions to Optimize Survival and Recovery in Patients With ARDS|
September 15 2022
Use of Extracorporeal Membrane Oxygenation Therapy During Pregnancy and COVID-19: A Case Study
Roberta Kaplow, PhD, APRN-CCNS, AOCNS, CCRN, FAAN;
Roberta Kaplow, PhD, APRN-CCNS, AOCNS, CCRN, FAAN
Roberta Kaplow is Clinical Nurse Specialist in the Acute Respiratory ICU, Emory University Hospital, 1364 Clifton Rd NE, Atlanta, GA 30319 ([email protected]).
Search for other works by this author on:
Casey Miller, MSN, RN, ANP-BC, AGACNP-BC
Casey Miller, MSN, RN, ANP-BC, AGACNP-BC
Casey Miller is ECMO Coordinator, Emory University Hospital, Atlanta, Georgia.
Search for other works by this author on:
AACN Adv Crit Care (2022) 33 (3): 247–252.
Citation
Roberta Kaplow, Casey Miller; Use of Extracorporeal Membrane Oxygenation Therapy During Pregnancy and COVID-19: A Case Study. AACN Adv Crit Care 15 September 2022; 33 (3): 247–252. doi: https://doi.org/10.4037/aacnacc2022111
Download citation file:
Sign in
Don't already have an account? Register
Short-term Access
Purchase short-term access on a pay-per-article or pay-per-issue basis.
$15 72 - hour single article access $30 7 - day full issue access